Table 2.
ncRNAs causing cardiovascular diseases.
| ncRNA | Disease condition | Effect | Description |
|---|---|---|---|
| miRNAs | |||
|
| |||
| miR-378 miR-122 miR-29 miR-26 |
Cardiac fibrosis | Negative, prognostic/diagnostic | Abnormal expression could induce cardiac fibrosis targeting TFG-β including miRNA [15] |
|
| |||
| miR-126 miR-17-92 cluster |
Endothelial dysfunction and inflammation | Negative, prognostic | Negative regulation of angiogenesis in epithelial cells [9] |
|
| |||
| miR-221 miR-222 miR-155 |
Initial stages of atherosclerosis | Positive, therapeutic | Inflammatory response of endothelial cells and showing antiangiogenic effects [9, 22] |
|
| |||
| miR-143 miR-145 |
Injured or atherosclerosis | Negative, prognostic | Regulation of phenotype of VSMCs in response to injury [9] |
|
| |||
| miR-21 miR-146a |
Vascular injury | Positive, therapeutic | Phenotypic modulation of VSMCs [9] |
|
| |||
| miR-208a | Acute Myocardial Infarction (AMI) | Negative, prognostic/diagnostic | Causes hypertrophic cardiac growth and fibrosis [13] |
|
| |||
| miR-23a | Pathological hypertrophy | Negative, prognostic/therapeutic | Upregulated as a result of hypertrophic stimuli in cardiomyocytes, downregulation can be done by ASO [13] |
|
| |||
| miR-29 miR-24 miR-320 |
Fibrosis and scar formation | Negative, prognostic | Expression levels drop after a myocardial infarction [13] |
|
| |||
| miR-19 miR-21 miR-146 miR-155 miR-133 |
Acute Coronary Syndrome (ACS) and coronary artery disease (CAD) | Negative, prognostic/diagnostic | Microparticles from plasma shows elevated amounts in ACS patients when compared to CAD patients [10, 23] |
|
| |||
| miR-1 miR-133 miR-208a |
Arrhythmias | Diagnostic | The presence of these miRNAs can be used as diagnostic features for arrhythmia, fibrosis, and metabolic disorders [24] |
| miR-21 miR-29 |
Fibrosis | Diagnostic | |
| miR-33 | Metabolic disorders | Diagnostic | |
|
| |||
| circRNAs | |||
|
| |||
| Heart Related Circular RNA (HRCR) | Cardiac hypertrophy and heart failure | Positive, prognostic/therapeutic | Protects the heart from pathological conditions caused by miR-223 by acting as its miRNA sponge resulting in increased amounts of ARC expressions. HRCR is therefore a target for drug development [15] |
|
| |||
| Cdr1as | Myocardial infarction injuries | Negative, prognostic | miR-7 sponge, the target genes of miR-7 are SP1 and PARP (poly-ADP-ribose polymerase) and they cause cell apoptosis; therefore the reduction in miR-7 increases the cell apoptosis causing SP1 and PARP [15] |
|
| |||
| Circ-Foxo3 | Cardiac senescence | Negative, diagnostic | Highly expressed in patients and causes cells to be held up at G1 phase unable to transit to S phase. Represses cell cycle progression and proliferation [15]. |
|
| |||
| Circular Antisense non coding RNA in INK4 locus (cANRIL) | Atherosclerosis risk | Negative, diagnostic | Regulate atherosclerosis [15] |